Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Inclusion criteria

• Provision of informed consent prior to any study specific procedures
• Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic agents between the age of 30 to 70
• Non-ST elevation Acute coronary syndrome with successful coronary stent implantation (with TIMI flow grade 3 after the procedure)

Exclusion criteria

• Hypersensitivity to ticagrelor, prasugrel or any of the excipients
• No prior use of either ticagrelor or prasugrel within a month prior to randomization.
• History of intracranial bleeding at any time
• Active pathologic bleeding
• Hemoglobin A1c >9%
• Type 1 diabetes
• Decreased serum platelet level (< 100,000/uL)
• Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
• Gastrointestinal bleed within the past 6 months, or major surgery within 30 days
• Renal failure requiring dialysis or anticipated need for dialysis during the course of the study
• Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study
• Involvement in the planning and/or conduct of the study
• Left ventricular ejection fraction < 40%
• Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase > twice the upper limit)
• Gastrointestinal disorder such as Crohn's disease
• Alcohol abuse
• Steroid or hormone replacement therapy
• Serum creatinine > 2.0 mg/dL.
• Prior history of CVA or stroke
• Body weight < 60 kg
• Life expectancy less than a year
• Known pregnancy, breast-feeding, or intend to become pregnant during the study period